| 1. |
- Ben-Menachem, Elinor, 1945
(författare)
-
Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures.
- 2008
-
Ingår i: Drugs of today (Barcelona, Spain : 1998). - : Clarivate Analytics (US). - 1699-3993. ; 44:1, s. 35-40
-
Tidskriftsartikel (refereegranskat)abstract
- Lacosamide, (R)-2-acetamido-N-benzyl-3-meth- oxypropionamide, is a new chemical entity specifically synthesized as an anticonvulsive drug candidate, which appears to have a novel dual mode of action. Its pharmacokinetic characteristics have been studied in young and elderly healthy adults, as well as in adults with epilepsy or diabetic neuropathic pain. After oral administration, lacosamide is rapidly and completely absorbed. An elimination half-life of 13 hours allows for twice-daily dosing. Lacosamide has a low potential for drug-drug interactions. Both oral and intravenous formulations of lacosamide are being developed. In completed placebo-controlled clinical trials, lacosamide has demonstrated efficacy as adjunctive therapy for reduction of seizure frequency in patients with uncontrolled partial-onset seizures, and has been generally well tolerated. For patients treated with lacosamide, the most frequently reported adverse events in placebo-controlled trials include dizziness, headache, nausea and diplopia. When used as short-term replacement for oral lacosamide, intravenous lacosamide has a comparable safety profile to oral lacosamide. Results from clinical trials to date suggest that lacosamide may be a useful pharmacological treatment option for patients with partial-onset seizures.
|
|
| 2. |
- Bulik, CM, et al.
(författare)
-
The genetics of bulimia nervosa
- 2004
-
Ingår i: Drugs of today (Barcelona, Spain : 1998). - : Clarivate Analytics (US). - 1699-3993 .- 0025-7656. ; 40:9, s. 741-749
-
Tidskriftsartikel (refereegranskat)
|
|
| 3. |
- Constantinescu, R, et al.
(författare)
-
Urate as a marker of development and progression in Parkinson's disease.
- 2011
-
Ingår i: Drugs of today (Barcelona, Spain : 1998). - : Clarivate Analytics (US). - 1699-3993. ; 47:5, s. 369-80
-
Tidskriftsartikel (refereegranskat)abstract
- Urate, a natural antioxidant and iron chelator, has emerged as a potentially promising compound that might prevent neurodegenerative disorders. However, hyperuricemia may cause gout and is associated with increased cardiovascular morbidity. This paper summarizes the impact of urate in the context of Parkinson's disease (PD). It reviews the association of serum urate with the risk of PD, the clinical progression in PD, cognitive, dietary and gender aspects, the relationship between gout and PD, and potential therapeutic implications for the future.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Kokaia, Merab, et al.
(författare)
-
The treatment of neurological diseases under a new light: the importance of optogenetics.
- 2011
-
Ingår i: Drugs of Today. - : Clarivate Analytics (US). - 1699-3993. ; 47:1, s. 53-62
-
Forskningsöversikt (refereegranskat)abstract
- Controlling activity of defined populations of neurons without affecting other neurons in the brain is now possible by a new gene- and neuroengineering technology termed optogenetics. Derived from microbial organisms, opsin genes encoding light-activated ion channels and pumps (channelrhodopsin-2 [ChR2]; halorhodopsin [NpHR], respectively), engineered for expression in the mammalian brain, can be genetically targeted into specific neural populations using viral vectors. When exposed to light with appropriate wavelength, action potentials can be triggered in ChR2-expressing neurons, whereas inhibition of action potentials can be obtained in NpHR-expressing neurons, thus allowing for powerful control of neural activity. Optogenetics is now intensively used in laboratory animals, both in vitro and in vivo, for exploring functions of complex neural circuits and information processing in the normal brain and during various neurological conditions. The clinical perspectives of adopting optogenetics as a novel treatment strategy for human neurological disorders have generated considerable interest, largely because of the enormous potential demonstrated in recent rodent and nonhuman primate studies. Restoration of dopamine-related movement dysfunction in parkinsonian animals, amelioration of blindness and recovery of breathing after spinal cord injury are a few examples of such perspectives.
|
|
| 7. |
- Mellstedt, H
(författare)
-
Monoclonal antibodies in human cancer
- 2003
-
Ingår i: Drugs of today (Barcelona, Spain : 1998). - 1699-3993. ; 3939 Suppl C, s. 1-16
-
Tidskriftsartikel (refereegranskat)
|
|
| 8. |
- Smelov, V, et al.
(författare)
-
CHLAMYDIA TRACHOMATIS SEROVAR DISTRIBUTIONS IN RUSSIAN MEN AND WOMEN : A COMPARISON WITH DUTCH SEROVAR DISTRIBUTIONS
- 2009
-
Ingår i: Drugs of Today. - 1699-3993. ; 45, s. 33-38
-
Tidskriftsartikel (refereegranskat)abstract
- The data on serovar distributions of Chlamydia trachomatis - the most diagnosed sexually transmitted infection (STI) worldwide - are important for epidemiologic purposes and transmission studies but ore completely locking in Russia. The aim of the current study is to determine the serogroup and serovar distributions in Russian men and women and compare these data with Dutch serogroup and serovar distributions. In Russian men and women, serogroup B was the most prevalent (46016), followed by the intermediate serogroup (I group; 33%) and serogroup C (27%). The distribution was comparable between men and women. The serogroup distribution was similar to the previously published distribution in Dutch cohorts. However, on a serovar level statistically very significant differences were observed, reaching up to P < 0.0001. The serovars B and G/Ga had higher prevalences compared with the reported Dutch prevalences, while serovars F, H, I/Ia, J and K hod lower prevalences compared with the Dutch studies. In conclusion, this is the first report of Russian C. trachomatis serovar/serogroup distributions. Serogroup 8 is the most prevalent, followed by serogroup I and serogroup C with no statistical differences on the serogroup level. However, significant differences between Russia and the Netherlands were observed in the distribution of C. trachomatis serovars.
|
|
| 9. |
- Stamatis, Pavlos, et al.
(författare)
-
Upadacitinib tartrate in rheumatoid arthritis
- 2020
-
Ingår i: Drugs of Today. - : Clarivate Analytics (US). - 1699-3993. ; 56:11, s. 723-732
-
Tidskriftsartikel (refereegranskat)abstract
- In rheumatoid arthritis (RA) there is an unmet therapeutic need, as a substantial proportion of patients does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs). The Janus kinase (JAK) inhibitors are the most recently added drug category in the therapeutic armamentarium in RA. Upadacitinib tartrate (Rinvoq), a selective and reversible JAK1 inhibitor, inhibited interleukin (IL)-6 and IL-7 and ameliorated adjuvant-induced arthritis in preclinical studies. In phase III randomized controlled trials (RCTs), upadacitinib, as monotherapy or in combination with csDMARDs, showed efficacy in RA patients with inadequate response to csDMARDs or bDMARDs. In a head-to-head RCT, upadacitinib 15 mg once daily was superior to adalimumab in achieving remission and in patient-reported outcomes. Upadacitinib has a good safety profile but it may increase the risk for herpes zoster, and as a substrate of cytochrome P450 (CYP) enzyme CYP3A4 it should not be coadministered with strong CYP3A4 inducers. Upadacitinib is contraindicated in patients with active tuberculosis, serious infections, active malignancy and in patients with severe liver impairment. Upadacitinib has been approved for the treatment of moderate to severe RA.
|
|
| 10. |
- Sylven, C
(författare)
-
Angiogenic gene therapy
- 2002
-
Ingår i: Drugs of today (Barcelona, Spain : 1998). - : Clarivate Analytics (US). - 1699-3993 .- 0025-7656. ; 38:12, s. 819-827
-
Tidskriftsartikel (refereegranskat)
|
|
